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Figure 1 
pH-Sensitive Mucoadhesive Film-Forming Gels 
Composition of Gel: 
' A solvent vehicle comprising at least 25% water 
I; I; A - Water-insoluble swellable mucoadhesive polymer(s) 
- pH-sensitive ?lm-forming polymer(s) 
~ Molecule of interest 
pH-Sensitive Mucoadhesive Wax-Film Composites 
Composition of Wax-Film Composite: 
A*: pH-sensitive mucoadhesive layer (comprised of the 
components of A above less the solvent vehicle) 
B: Water-insoluble wax layer with water-soluble or water 
swellable polymer 
Note: Molecule of interest is contained in either A* or B, or both 
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Figure 2 
ln-Vitro Adhesion Time of Wax-Film 
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Figure 3 
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Figure 5 
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Figure 6 
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Figure 8 
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Figure 11 
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Figure 12 
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PH-SENSITIVE MUCOADHESIVE 
FILM-FORMING GELS AND WAX-FILM 
COMPOSITES SUITABLE FOR TOPICAL 
AND MUCOSAL DELIVERY OF MOLECULES 
This application is a divisional of, and claims a bene?t of 
priority under 35 U.S.C. § 120 from, application Ser. No. 
09/748,133 ?led Dec. 27, 2000 now US. Pat. No. 7,803,392. 
FIELD OF THE INVENTION 
The present invention relates to compositions and methods 
to treat the skin and mucosal surfaces with mucoadhesive 
?lm-forming gels and wax-?lm composites that are pH-sen 
sitive. The invention also relates to using such pH-sensitive 
?lm-forming gels and wax-?lm composites to deliver mol 
ecules of interest, namely active pharmaceuticals. The inven 
tion also relates to the use of said pH-sensitive ?lm-forming 
gels and wax-?lm composites to deliver molecules of interest, 
such as small molecules, peptides, proteins, and nucleic acids 
either locally to act at the site of administration or for the 
absorption of said molecules of interest across biological 
membranes into the systemic circulation. 
BACKGROUND OF THE INVENTION 
Pharmaceutical formulations intended to deliver drugs 
topically, either for local action at the site of administration or 
for absorption into the systemic circulation, have been 
described in the literature. These formulations are designed 
either for adherence of the dosage form to the skin (for dermal 
or transderrnal delivery of drugs) or mucosal surface (for 
mucosal or transmucosal delivery of drugs). For skin delivery, 
formulations generally consist of dermal patches, pastes, 
band-aids, gels, lotions, sprays, or creams. For mucosal deliv 
ery, formulations generally consist of gels, creams, tablets, 
sprays, or ?lms. In either case, one speci?c requirement is that 
the dosage form remains at the administration site for a suf 
?cient amount of time so that the drug may function as 
needed. A second speci?c requirement is that the dosage form 
must consist of pharmaceutically acceptable materials. Many 
of the reported and commercially available delivery systems 
intended for topical and mucosal delivery are aqueous-based 
formulations comprising water-soluble excipients. However, 
these systems tend to be easily and quickly washed away from 
the application site within minutes after application. This is 
very undesirable if the drug must remain at the application 
site for a prolonged period in order to be ef?cacious. In an 
attempt to prolong the residence time at the application site, 
researchers have described the use of water-insoluble excipi 
ents in the formulations. However, most often the use of 
water-insoluble excipients necessitates the use of non-aque 
ous solvents to dissolve the excipients. Excessive and 
repeated administration of non-aqueous solvents is not desir 
able. 
Different types of formulations to deliver drugs topically 
are known in the art. Speci?c examples are illustrated below. 
US. Pat. No. 4,715,369 by Suzuki et al. relates to methods 
to treat the injured oral mucosa with a thin two-layer tablet 
comprised of both an adhesive layer and a nonadhesive layer. 
The adhesive layer is comprised of water-soluble cellulose 
based polymers and polyacrylic acid while the nonadhesive 
layer is comprised mostly of materials with no adhesive prop 
erties. The Suzuki patent does not teach the use of ?lm 
forming gels comprised of pH-sensitive polymers and water 
insoluble mucoadhesive polymers that form ?lms due to 
changes in pH and/or desolvation of the polymers. Further, 
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the Suzuki patent does not teach the use of pH-sensitive 
wax-?lm composites intended to remain adhered to the skin 
or mucosal surface for a prolonged period of time. 
US. Pat. No. 5,800,832 by Tapolsky et al. relates to a 
water-soluble, bioerodable device for the delivery of drugs, 
and speci?cally dyclonine, to mucosal surfaces. The device 
comprises an adhesive layer as well as a non-adhesive layer. 
Both the adhesive layer and the nonadhesive layer consist of 
water-soluble polymers such as cellulose-based polymers. 
The Tapolsky patent does not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/or desolvation of the polymers. Further, the Tapolsky 
patent does not teach the use of pH-sensitive wax-?lm com 
posites intended to remain adhered to the skin or mucosal 
surface for a prolonged period of time. 
US. Pat. No. 5,955,097 by Tapolsky et al. relates to a non 
water-soluble gel, which adheres to mucosal surfaces and 
body tissues upon application and forms a ?lm. The gel com 
prises at least one water-insoluble cellulose-based polymer, a 
non-aqueous solvent, and at least one active pharmaceutical. 
The patent teaches that upon application to the mucosal sur 
face or skin, the non-aqueous solvent, primarily ethanol, 
evaporates, diffuses, or penetrates the surrounding tissue, 
resulting in precipitation of the non water-soluble polymers 
into ?lms. The Tapolsky patent further teaches the use of 50 to 
80% ethanol by weight in the pharmaceutical gel. The Tapol 
sky patent does not teach the use of ?lm-forming gels con 
taining at least 25% water by weight and comprised of pH 
sensitive polymers and water-insoluble mucoadhesive 
polymers that form ?lms due to changes in pH and/ or desol 
vation of the polymers. Further, the Tapolsky patent does not 
teach the use of pH-sensitive wax-?lm composites intended 
to remain adhered to the skin or mucosal surface for a pro 
longed period of time. 
US. Pat. No. 5,780,045 by McQuinn et al. relates to a 
transmucosal drug delivery device in the form of a sheet 
comprising an acid-containing particulate polymer dispersed 
in a polytetra?uoroethylene support matrix. The McQuinn 
patent does not teach the use of ?lm-forming gels comprised 
of pH-sensitive polymers and water-insoluble mucoadhesive 
polymers that form ?lms due to changes in pH and/ or desol 
vation of the polymers. Further, the McQuinn patent does not 
teach the use of pH-sensitive wax-?lm composites intended 
to remain adhered to the skin or mucosal surface for a pro 
longed period of time. 
US. Pat. No. 4,552,751 by Inaba et al. relates to the prepa 
ration of multi-layered ?lms of three, ?ve, or seven layers for 
the administration of speci?c prostaglandins to mucosal sites. 
The Inaba patent does not teach the use of ?lm-forming gels 
comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, the Inaba patent 
does not teach the use of pH-sensitive wax-?lm composites 
intended to remain adhered to the skin or mucosal surface for 
a prolonged period of time. 
US. Pat. No. 4,517,173 by Kizawa et al. relates to a ?lm 
preparation consisting of at least three layers, including a 
pharmaceutical layer, a poorly water-soluble layer, and an 
intermediate layer. The pharmaceutical layer consists of pre 
donisolone and allantoin together with a water-soluble cellu 
lose-based polymer. The poorly water-soluble layer consists 
of shellack or fatty acids. The Kizawa patent does not teach 
the use of ?lm-forming gels comprised of pH-sensitive poly 
mers and water-insoluble mucoadhesive polymers that form 
?lms due to changes in pH and/or desolvation of the poly 
mers. Further, the Kizawa patent does not teach the use of 
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pH-sensitive wax-?lm composites intended to remain 
adhered to the skin or mucosal surface for a prolonged period 
of time. 
U.S. Pat. No. 5,192,802 by Rencher describes the use of a 
bioadhesive teething gel comprising benzocaine, sodium car 
boxy methyl cellulose; an agent selected from the group 
consisting of xanthan gum and sodium alginate and a diluent 
selected from the group consisting of polyethylene glycol and 
polyethylene glycol with glycerine. U.S. Pat. No. 5,314,915 
by Rencher and Us. Pat. No. 5,298,258 by Akemi et al. also 
describe the use of aqueous or oil-based bioadhesive gelling 
agents. These patents do not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, these patents do 
not teach the use of pH-sensitive wax-?lm composites 
intended to remain adhered to the skin or mucosal surface for 
a prolonged period of time. 
U.S. Pat. Nos. 5,081,157 and 5,081,158 by PomerantZ 
relate to a ?lm-forming composition for topical application of 
medicaments to body tissues. The ?lm-forming composition 
includes hydroxypropyl cellulose, a volatile solvent, and an 
esteri?cation agent which reacts with the hydroxypropyl cel 
lulose to form a reaction product which is soluble in the 
solvent. These patents do not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, these patents do 
not teach the use of pH-sensitive wax-?lm composites 
intended to remain adhered to the skin or mucosal surface for 
a prolonged period of time. 
U.S. Pat. No. 4,900,554 by Yanagibashi et al. relate to the 
use of a device for the delivery of drugs in the oral cavity. The 
device comprises an adhesive layer consisting of at least one 
acrylic acid polymer, a water-insoluble cellulose derivative, 
and a pharmaceutical preparation, and a water-insoluble or 
sparingly soluble backing layer. Yanagibashi et al. state that 
“it is impossible to achieve an adhesive device for application 
to body tissue without all three components, that is, acrylic 
acid polymer, water insoluble cellulose derivative and water 
insoluble or sparingly soluble backing layer”. The 
Yanagibashi patent does not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, the Yanagibashi 
patent does not teach the use of pH-sensitive wax-?lm com 
posites intended to remain adhered to the skin or mucosal 
surface for a prolonged period of time. 
As illustrated, the references described above appear to 
lack preferred compositions and properties for an ef?cacious 
and pharmaceutically acceptable bioadhesive delivery sys 
tem. Namely, the references do not describe primarily aque 
ous-based ?lm-forming gels comprised of pH-sensitive poly 
mers and water-insoluble mucoadhesive polymers that form 
?lms due to changes in pH and/or desolvation of the poly 
mers. Further, the references do not describe pH-sensitive 
mucoadhesive wax-?lm composites intended to remain 
adhered to the skin or mucosal surface for a prolonged period 
of time. 
SUMMARY OF THE INVENTION 
The invention is directed to a pharmaceutical gel compo 
sition comprising: 
a solvent vehicle, 
at least one water-insoluble swellable mucoadhesive poly 
mer, 
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at least one pH-sensitive ?lm-forming polymer, and 
at least one molecule of interest. 
The solvent vehicle may be comprised of at least 25 to 100 
parts water or buffered water with 0 to 75 parts of ethanol, 
propylene glycol, glycerin, polyethylene glycol, or combina 
tions thereof. The water-insoluble swellable mucoadhesive 
polymer may be polyacrylic acid cross-linked with polyalk 
enyl ether or divinyl glycol, wherein the water-insoluble 
swellable mucoadhesive polymer is preferably, Noveon or 
Carbomer. The water-insoluble swellable mucoadhesive 
polymer may be present at a concentration of from 0.1% to 
20% by weight. 
The pH-sensitive polymer is a copolymer of methacrylic 
acid and acrylic or methacrylic ester. Preferably, it is present 
at a concentration of from 0.05% to 10% by weight. More 
preferably, the polymer is a Eudragit polymer, or a chemical 
derivative thereof. 
The molecule of interest may comprise an active pharma 
ceutical such as an antimicrobial, antiviral, antiin?ammatory, 
antiseptic, antihistamine, a local anesthetic, a disinfectant, a 
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a 
sweetener, a ?avoring agent, a diagnostic agent, or combina 
tion thereof. Preferably, the molecule of interest is amlex 
anox, triclosan, peptide, protein, hirudin, plasmid DNA, 
lidocaine, benzocaine, dyclonine, or benzodiazepine drug or 
a derivative thereof. 
The invention is also directed to a pharmaceutical gel 
which when applied to the skin or mucosal surface forms a 
?lm, said gel comprising a solvent vehicle, at least one water 
insoluble swellable mucoadhesive polymer, at least one pH 
sensitive ?lm-forming polymer, and at least one molecule of 
interest, wherein said ?lm is formed due to changes in pH and 
desolvation of the polymer, and wherein said ?lm provides 
for the delivery of the molecule of interest to or through the 
application site. The solvent vehicle may be comprised of at 
least 25 to 100 parts water with 0 to 75 parts of ethanol, 
propylene glycol, glycerin, polyethylene glycol, or combina 
tions thereof. The water-insoluble swellable mucoadhesive 
polymer may be polyacrylic acid cross-linked with polyalk 
enyl ether or divinyl glycol. Preferably, the water-insoluble 
swellable mucoadhesive polymer is Noveon or Carbomer. 
The water-insoluble swellable mucoadhesive polymer may 
be present at a concentration of from 0.1% to 20% by weight. 
The pH-sensitive polymer may be a copolymer of meth 
acrylic acid and acrylic or methacrylic ester. Preferably, it is 
present at a concentration of from 0.05% to 10% by weight. 
More preferably, the polymer is a Eudragit polymer, or a 
chemical derivative thereof. 
The molecule of interest may comprise an active pharma 
ceutical such as an antimicrobial, antiviral, antiin?ammatory, 
antiseptic, antihistamine, a local anesthetic, a disinfectant, a 
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a 
sweetener, a ?avoring agent, a diagnostic agent, or combina 
tion thereof. Preferably, the molecule of interest is amlex 
anox, triclosan, peptide, protein, hirudin, plasmid DNA, 
lidocaine, benzocaine, dyclonine, or benzodiazepine drug or 
a derivative thereof. The application site may be the skin, 
mouth, vagina, nose, nasal cavity, or other accessible mucosal 
site. 
The invention is also directed to a wax-?lm composite 
comprised of a pH-sensitive mucoadhesive layer and a water 
insoluble wax layer. The pH-sensitive mucoadhesive layer 
may be present at a concentration of 20% to 90% by weight, 
and the water-insoluble wax layer may be present at a con 
centration of 10% to 80% by weight. The pH-sensitive 
mucoadhesive water-insoluble layer may be comprised of: 
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at least one water-insoluble swellable mucoadhesive poly 
mer, 
at least one pH-sensitive ?lm-forming polymer, and 
at least one molecule of interest. 
The water-insoluble swellable mucoadhesive polymer is 
polyacrylic acid cross-linked with polyalkenyl ether or divi 
nyl glycol. Preferably, the water-insoluble swellable mucoad 
hesive polymer is Noveon or Carbomer. 
The pH-sensitive polymer may be a copolymer of meth 
acrylic acid and acrylic or methacrylic ester. More preferably, 
the polymer is a Eudragit polymer, or a chemical derivative 
thereof. 
The molecule of interest may comprise an active pharma 
ceutical such as an antimicrobial, antiviral, antiin?ammatory, 
antiseptic, antihistamine, a local anesthetic, a disinfectant, a 
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a 
sweetener, a ?avoring agent, a diagnostic agent, or combina 
tion thereof. Preferably, the molecule of interest is amlex 
anox, triclosan, hirudin, plasmid DNA, lidocaine, ben 
zocaine, dyclonine, or benzodiazepine drug or a derivative 
thereof. The wax-?lm composite may comprise at least one 
water-insoluble pharmaceutical wax having a melting point 
between 40° C. and 100° C. and at least one water-soluble or 
water-swellable polymer. 
The wax may be DENTSPLY® Utility Wax, beeswax, 
emulsifying wax, microcrystalline wax, carnauba wax, par 
a?in wax, white wax, yellow wax, or other suitable pharma 
ceutical wax. The water-soluble or swellable polymer may be 
present in the insoluble wax layer at a concentration of 0.05 to 
10% by weight. The water-soluble or swellable polymer may 
be tragacanth, polyvinyl pyrrolidone, polyvinyl alcohol, 
cross-linked polyacrylic acid, polyethylene glycol, a cellu 
lose polymer derivative, or other suitable pharmaceutical 
polymer that is water-soluble or water-swellable. In the wax 
?lm composite, the molecule of interest may be contained in 
and released from either the pH-sensitive mucoadhesive layer 
or the water-insoluble wax layer. 
The molecule of interest comprises an active pharmaceu 
tical compound such as an antimicrobial, antiviral, antiin 
?ammatory, antiseptic, antihistamine, a local anesthetic, a 
disinfectant, a keratolytic, an analgesic, an anti-migraine, an 
anti-fungal, a sweetener, a ?avoring agent, a diagnostic agent, 
or a combination thereof. The molecule of interest may com 
prise an active pharmaceutical such as an antimicrobial, anti 
viral, antiin?ammatory, antiseptic, antihistamine, a local 
anesthetic, a disinfectant, a keratolytic, an analgesic, an anti 
migraine, an anti-fungal, a sweetener, a ?avoring agent, a 
diagnostic agent, or combination thereof. Preferably, the mol 
ecule of interest is amlexanox, triclosan, protein, peptide, 
hirudin, plasmid DNA, lidocaine, benzocaine, dyclonine, or 
benzodiazepine drug or a derivative thereof. Preferably, the 
hirudin may be complexed with a substance of opposite 
charge. More preferably, the substance of opposite charge 
may be chitosan or protamine. Alternatively, the molecule of 
interest may be a plasmid DNA or plasmid DNA complexed 
with a substance of opposite charge such as chitosan, prota 
mine, or a cationic lipid. 
The application site for the wax-?lm composite may be the 
skin, mouth, vagina, nasal cavity, or other accessible mucosal 
site. Preferably, the wax-?lm composite adheres to the appli 
cation site for at least 1 hour. Preferably, the wax-?lm com 
posite has a total thickness of less than 5 mm. 
The invention is also directed to a method of making the 
above pharmaceutical gel composition, comprising: 
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(i) adding a mucoadhesive polymer to a stirring water to 
form a solution that is clear and viscous, 
(ii) adding the pH-sensitive ?lm-forming polymer to the 
solution formed in step (i) and measuring the pH of the 
solution, 
(iii) adding the molecule of interest to the solution of step 
(ii), and 
(iv) forming the ?nal gel composition. 
The invention is also directed to a method of making the 
above wax-?lm composite, comprising: 
(i) forming a homogeneous mucoadhesive ?lm by fusing a 
mucoadhesive polymer and a pH-sensitive ?lm-forming 
polymer, 
(ii) homogeneously coating one side of the mucoadhesive 
?lm of step (i) with a melted wax composition, and 
(iii) drying the wax composition to form the wax-?lm 
composite, wherein the molecule of interest is added in 
either step (i) or (ii), or the molecule of interest is added 
to the mucoadhesive side after the wax-?lm composite is 
formed. 
Furthermore, the invention is also directed to a method of 
treating a disease or an illness by administering to a person in 
need thereof, the gel or the wax-?lm composite as described 
above comprising a molecule of interest. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention will become more fully understood 
from the detailed description given hereinbelow, and the 
accompanying drawings which are given by way of illustra 
tion only, and thus are not limitative of the present invention, 
and wherein; 
FIG. 1 shows a summary of the compositions of the inven 
tion 
FIG. 2 shows an in vitro adhesion time of 1A inch wax-?lm 
composites (n:3 each) on glass submerged in 40 mM 
KHZPO4/NaOH buffer, pH 6 at 37° C. (unstirred). Each 
mucoadhesive layer contains 5.0-5.3 mg of total polymer 
comprised of Noveon and Eudragit S100 in the ratios indi 
cated. The wax layer consists of DENTSPLY® Utility Wax 
containing 1% w/w tragacanth polymer. *Indicates that dif 
ferent volumes of mucoadhesive gels were cast as described 
in Example 8. See Table 1 and Example 8 for additional 
details. 
FIG. 3 shows in vitro adhesion time of 1A inch wax-?lm 
composites (n:3 each) on glass submerged in 40 mM 
KH2PO4/NaOH buffer, pH 6 at 37° C. (stirred at 100 rpms). 
Each mucoadhesive layer contains from 1.2 mg to 11.2 mg of 
total polymer comprised of Noveon and Eudragit S100 in a 
weight ratio of 3:1. The wax layer consists of DENTSPLY® 
Utility Wax containing 1% w/w tragacanth polymer. See 
Table 2 and Example 9 for additional details. 
FIG. 4 shows in vitro adhesion time of 1A inch wax-?lm 
composites containing plasmid DNA (10 pg) either incorpo 
rated during the manufacturing process (‘preload’) or ali 
quoted onto the mucoadhesive layer after the manufacturing 
process (‘postload’). Wax-?lm composites (n:5 each) were 
adhered to glass and submerged in 40 mM KHZPO4/NaOH 
buffer, pH 6 at 37° C. (unstirred). See Example 10 for addi 
tional details. 
FIG. 5 shows a standard curve forplasmid DNA in solution 
as measured by the PicoGreen DNA Quantitation Kit (from 
Molecular Probes, Inc., Eugene, Oreg.). 
FIG. 6 shows the release of plasmid DNA pre-loaded into 
wax-?lm composites. Wax-?lm composites were made as 
described in Example 10 using a mucoadhesive gel com 
prised of Noveon/Eudragit S100 (3:1 w/w) and plasmid 
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DNA. The wax layer consists of DENTSPLY® Utility Wax 
containing 1% w/w tragacanth polymer. Five 1A inch wax 
?lm composites containing of plasmid DNA (5 pg) were 
submerged separately into 1 mL 10 mM PBS buffer, pH 7.4 at 
370 C. At various times, exactly 100 ML solution was ali 
quoted for DNA quantitation using the PicoGreen DNA 
Quantitation Kit. Exactly 100 ML fresh PBS was added to 
replace the removed volume at each time point. 
FIG. 7 shows the release of plasmid DNA post-loaded into 
wax-?lm composites. Wax-?lm composites were made as 
described in Example 10 using a mucoadhesive gel com 
prised of Noveon/Eudragit S100 (3:1 w/w). The wax layer 
consists of DENTSPLY® Utility Wax containing 1% w/w 
tragacanth polymer. Plasmid DNA (5 pg) was added to ?ve 
individual 1A inch wax-?lm composites, allowed to air dry for 
4 hours, and then submerged separately into 1 mL 10 mM 
PBS buffer, pH 7.4 at 370 C. At various times, exactly 100 ML 
solution was aliquoted for DNA quantitation using the 
PicoGreen DNA Quantitation Kit. Exactly 100 ML fresh PBS 
was added to replace the removed volume at each time point. 
FIG. 8 shows: (A) The reaction kinetics of Chromozym 
TH and uncomplexed thrombin. Hirudin was added to excess 
thrombin and residual uncomplexed thrombin was assayed 
spectroscopically after the addition of Chromozym-TH. 
Hirudin was added to the 1.0 ml volume in the following 
amounts: 0 ng (III), 16.9 ng (C), 33.8 ng (A), 50.7 ng (A), 67.6 
ng (0), and 84.4 ng (I). (B) Calibration curve for released 
hirudin in solution. The ?gure was made by plotting the 
difference between the thrombin base value absorbance 
(thrombin in the presence of substrate only) and the hirudin 
sample values versus the concentration of hirudin standards 
from A. 
FIG. 9 shows an HPLC Standard Curve for Hirudin. Three 
standard curves for hirudin were generated using a C18 
Nucleosil® 5 pm analytical column (4.6><250 mm). The 
mobile phase consisted of water:acetonitrile:tri?uoroacetic 
acid (59.95:40:0.05 w/w/w). The ?ow rate was 0.6 mL/min. 
Each 50 ML sample of each standard curve was injected three 
times and the average AUC was plotted. 
FIG. 10 shows the Particle Size of Hirudin/Chitosan Com 
plexes in water made with hirudin at a Concentration of 0.5 
mg/mL. 
FIG. 11 shows the Zeta Potential of Hirudin/Chitosan 
Complexes in water made with Hirudin at a Concentration of 
0.1 mg/mL. Zeta Potential values are reported as the mean 
and standard deviation of three measurements. 
FIG. 12 shows the stability of Hirudin/Chitosan Com 
plexes (4:1 w/w) made in water as function of Hirudin con 
centration and storage time. All samples were stored at 4° C. 
For the Day 7 sample analysis, exactly 100 ML of Hirudin/ 
Chitosan complexes in water was diluted in 900 ML ethanol to 
determine the stability of the complexes in ethanol. 
DETAILED DESCRIPTION OF THE INVENTION 
The invention relates to delivery systems suitable for the 
topical and mucosal delivery of molecules of interest. Spe 
ci?cally, the invention relates to; 1) compositions of pH 
sensitive mucoadhesive ?lm-forming gels, 2) uses of pH 
sensitive mucoadhesive ?lm-forming gels, 3) compositions 
of pH-sensitive mucoadhesive wax-?lm composites, and 4) 
uses of pH-sensitive mucoadhesive wax-?lm composites. A 
summary of the compositions of the invention is shown in 
FIG. 1. 
The pH-sensitive mucoadhesive ?lm-forming gel is a phar 
maceutical gel which when applied to the skin or mucosal 
surface forms a ?lm, said gel comprising a solvent vehicle, at 
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least one water-insoluble swellable mucoadhesive polymer, 
at least one pH-sensitive ?lm-forming polymer, and at least 
one molecule of interest, said ?lm forming due to changes in 
pH and desolvation of the polymer, said ?lm providing for the 
delivery of the molecule of interest to or through the applica 
tion site. 
The pH-sensitive mucoadhesive wax-?lm composite is a 
bi-layer pharmaceutical ?lm less than 5 mm in diameter that 
when applied to the skin or mucosal surface adheres to the 
application for at least 1 hour. The wax-?lm composite is 
comprised of a pH-sensitive mucoadhesive layer and a water 
insoluble wax layer. 
De?nitions and Preferred Embodiments 
As used herein, certain terms may have the following 
de?ned meanings. 
As used in the speci?cations and claims, the singular form 
a, an and the include plural references unless the context 
clearly dictates otherwise. For example, the term a pharma 
ceutical may refer to one or more pharmaceuticals for use in 
the presently disclosed formulations and methods. 
The term molecule of interest is de?ned as any synthetic or 
naturally occurring substance including elements, radioac 
tive elements, synthetic or natural small molecules, peptides, 
proteins, nucleic acids, or any combinations thereof. 
The term active pharmaceutical means any synthetic or 
naturally occurring substance including elements, radioac 
tive elements, synthetic or natural small molecules, peptides, 
proteins, nucleic acids, or any combinations thereof intended 
to be administered to a warm-blooded mammal to elicit a 
pharmacological response. The terms pharmaceutical, active 
pharmaceutical, and drug as used herein are identical in 
meaning and thus are used interchangeably. It is preferred that 
the active pharmaceutical be an anti-microbial, antiviral, anti 
in?ammatory, antiseptic, antihistamine, tranquilizer, seda 
tive, anti-nausea, local anesthetic, disinfectant, keratolytic, 
analgesics including anti-migraine, anti-fungal, sweetener, 
?avoring agent, diagnostic agent, peptide, protein, antigen, 
monoclonal antibody, polyclonal antibody, nucleic acid, or 
combinations thereof. More preferably, the active pharma 
ceutical is amlexanox, triclosan, lidocaine, dyclonine, ben 
zocaine, a benzodiazepine, hirudin, antisense oligonucle 
otide, or plasmid DNA, or any derivative or combinations 
thereof. 
Amlexanox: The chemical name of Amlexanox is 
2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano-[2,3 
b]-pyridine-3-carboxylic acid. Amlexanox is the active ingre 
dient in the commercial product, Aphthasol, which acceler 
ates the healing of aphthous ulcers in the mouth by an 
unknown mechanism (Binnie et al. 1997; Khandwala et al. 
1997a; Khandwala et al. 1997b). The Aphthasol product is a 
5% paste. In cell culture experiments, Amlexanox has been 
shown to inhibit the formation or release of in?ammatory 
mediators such as histamine and leukotrienes from mast cells, 
neutrophils, and mononuclear cells (Urisu et al. 1990). Eur 
ther, in animals, Amlexanox has anti-allergic and anti-in?am 
matory properties and has been shown to inhibit both imme 
diate and delayed hypersensitivity reactions (Saijo et al. 
1985; Saijo et al. 1986). Amlexanox has very poor solubility 
in ethanol (0.58 mg/mL) and water (0.005 mg/mL). However, 
the solubility of Amlexanox increases with pH. 
Triclosan: The chemical name of Triclosan is 2,4,4' 
Trichloro 2'-hydroxy-diphenylether 5-chloro 2-(2,4-dichlo 
rophenoxy)-phenol. Triclosan is a broad-spectrum antibacte 
rial that has activity against a wide range of gram-positive and 
gram-negative bacteria (Zuckerbraun et al. 1998). Triclosan 
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has been shown to inhibit bacterial fatty acid synthesis at the 
enoyl-acyl carrier protein reductase (FabI) step (Heath et al. 
1999). It has gained wide-spread use as antibacterial agent 
that is used in toothpastes, kitchen utensils and toys. Triclosan 
has also been formulated in mouthwashes (Mandel 1994) and 
liposomes (Jones et al 1993). Triclosan has a pKa of7.9 and 
is insoluble in water, except in alkaline solutions where it is 
readily soluble (Loftsson et al. 1999). However, triclosan is 
soluble in ethanol and polyethylene glycol 400 and many 
other organic solvents. 
Hirudin: Hirudin is the most potent and speci?c known 
inhibitor of thrombin (Kl-:02 pM) (Markwardt 1989; Mark 
wardt 1991a; Markwardt 1991b; Fenton et al. 1991). Hirudin 
was originally isolated from medicinal leeches (Hirudo 
medicinalis), but is now available in large quantities due to 
recombinant techniques (Riehl-Bellon et al. 1989). Unlike 
heparin, hirudin does not require endogenous cofactors to 
function and does not have associated bleeding complica 
tions. Hirudin is a relatively small 65 amino acidpeptide (Mw 
7000) with remarkable stability over a broad range of pH (pH 
3-10), temperature (i.e., up to 60° C.), and solvent conditions 
(Chang 1991; Eric and Caroline 1991). The main structure of 
hirudin is characterized by an apolar disul?de knot with a 
very anionic (negatively-charged) tail. The apolar knot of 
hirudin masks the catalytic site of thrombin by interacting 
with its apolar site (i.e., via hydrophobic interaction). The 
anionic tail of hirudin (18 amino acids) interacts with the 
anion-binding exosite of thrombin. It is the combination of 
the apolar binding and the anion-binding that accounts for the 
very high af?nity of hirudin and thrombin. The presence of 
the apolar knot and anionic tail on hirudin results in both 
hydrophobic and hydrophilic surface interactions. For 
example, in solution, hirudin forms micellar complexes (e.g., 
tetramers) with itself. Further, the apolar region of hirudin is 
known to interact with cell membranes while the anionic tail 
remains extracellular (Fenton 1989). It is likely that the 
anionic portion of hirudin is electrostatically repelled from 
the surface of cell membranes. Novartis Pharma obtained 
marketing approval in the European Union in 1998 for 
REVASC (desirudin; recombinant hirudin) for the prevention 
of deep-vein thrombosis following knee and hip replacement 
surgery. In clinical trials, patients receiving hirudin by sub 
cutaneous injection twice a day for 8 days had a nearly 30% 
lower overall rate of deep-vein thrombosis than those who 
received low molecular weight heparin (Eriksson et al. 1997). 
Novartis is also performing clinical trials (Phase III) for the 
use hirudin in acute coronary syndrome. Several other indi 
cations for hirudin are being pursued such as stasis-induced 
venous thrombosis, diffuse microthrombosis, and hemodi 
alysis (Markwardt 1989). Most of the potential applications 
of hirudin require blood levels between 80 to 3500 ng/mL 
(Markwardt 1989, Markwardt 1991). A potential problem 
with the use of injected forms of hirudin is that there are no 
effective antidotes for hirudin overdosing. If upon frequent 
injection, the wrong dose is given, there are no methods to 
turn the activity of hirudin off. For this reason alone, hirudin 
is a good candidate for transmucosal delivery via the buccal 
tissue. It is envisioned that the pH-sensitive mucoadhesive 
?lm-forming gel or wax-?lm composite containing hirudin, 
can easily be applied to the buccal tissue in the mouth and 
provide a means to safely control the dosing and dose sched 
uling of hirudin. 
Benzodiazepines: Benzodiazepines are among the most 
frequently prescribed drugs in the Western world. All benzo 
diazepine agonists exert similar pharmacodynamic actions 
(e.g., activate central GABAergic neuroinhibition, thereby 
inducing anxiolysis, sedation/hypnosis, anticonvulsion and 
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muscle relaxation. In turn, benzodiazepines are used for the 
treatment of seizures and insomnia, preoperative or proce 
dural sedation, and for the treatment of nausea and anxiety. 
Most if not all of the benzodiazepine bases have little or no 
solubility in water and are very lipophilic (Hjortkjaer et al. 
1999, Bechgaard et al. 1997). As a result, a great deal of 
research has gone into developing ef?cacious dosage forms 
of these drugs including; i) synthesizing water-soluble 
derivatives such as their hydrochloride salts, ii) developing 
injectable formulations of the benzodiazepine bases that do 
not result in precipitation of the drugs, and iii) exploring 
alternative routes of administration including intranasal, rec 
tal, and buccal. Previous work has shown that intranasal doses 
of the benzodiazepine bases dissolved in organic solvents 
lead to pharmacological responses with suitable pharmaco 
kinetic pro?les. However, the repeated use of organic solvents 
such as ethanol, polyethylene glycol, and propylene glycol 
for intranasal administration is not desirable. Alternatively, 
benzodiazepines have been given by buccal administration 
with very favorable results (Schwagmeier et al. 1998; Scott et 
al. 1999). For example, Schwagmeier et al. showed that the 
maximum plasma concentration of midazolam was 55.9 
ng/mL at 30 minutes following buccal administration of 5 mg 
midazolam with a mean bioavailability of 74.5%. Scott et al. 
reported that the buccal administration of 10 mg midazolam 
per 2 mL stopped 75% (30/40) seizures in children within an 
average time of 6 minutes after administration. Thus, buccal 
administration of benzodiazepines may be an attractive alter 
native to injection or intranasal administration. It is envi 
sioned that the said pH-sensitive mucoadhesive ?lm-forming 
gel or wax-?lm composite containing a benzodiazepine can 
easily be applied to the buccal tissue in the mouth and provide 
a means to safely and reproducibly deliver doses of the ben 
zodiazepines for the treatment of seizures and insomnia, pre 
operative or procedural sedation, and for the treatment of 
nausea and anxiety. Benzodiazepines suitable for delivery 
are, but not limited to, alprazolam, camazepam, clobazam, 
clonazepam, desmethyldiazepam, diazepam, ?unitrazepam, 
?urazepam, halazepam, lorazepam, lormethazepam, mida 
zolam, nitrazepam, oxazepam, pinazepam, prazepam, triaz 
olam, and derivatives and combinations thereof. 
The term pharmaceutically acceptable means that the sub 
stance is generally regarded to be safe when used in such a 
manner that is widely acceptable by those skilled in the art. 
For reference of acceptable materials, refer to THE UNITED 
STATES PHARMACOEPIA. 
The term pH-sensitive is de?ned as a substance that is 
affected by changes in pH so that the substance changes 
conformation, charge, solubility, or combinations thereof. A 
pH-sensitive polymer is de?ned as polymer that is affected by 
changes in pH so that the polymer changes conformation, 
charge, solubility, or combinations thereof. A pH-sensitive 
?lm-forming polymer is de?ned as polymer that is affected by 
changes in pH so that the polymer changes conformation, 
charge, solubility, or combinations thereof resulting in the 
precipitation, desolvation, or settling of the polymer into a 
?lm. For the purposes of this invention, it is preferred that the 
pH-sensitive ?lm-forming polymers have some solubility in 
aqueous-based vehicles above pH 5 but limited or no solubil 
ity below pH 5. It is more preferred that the pH-sensitive 
?lm-forming polymers have some solubility in aqueous 
based vehicles above pH 6 but limited or no solubility below 
pH 6. It is most preferred that the pH-sensitive ?lm-forming 
polymers have some solubility in aqueous-based vehicles 
above pH 7 but limited no solubility below pH 7. Examples of 
pH-sensitive ?lm-forming polymers that meet these criteria 










